CRVO CERVOMED INC

CervoMed to Participate in Upcoming Investor Conferences

CervoMed to Participate in Upcoming Investor Conferences

BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that Company management will participate in the following investor conferences during the month of September:

H.C. Wainwright 27th Annual Global Investment Conference

Format: Presentation & 1x1 Investor Meetings

Presentation Date: Monday, September 8, 2025

Presentation Time: 2:00 – 2:30 PM ET

Webcast:

Morgan Stanley’s 23rd Annual Global Healthcare Conference

Format: 1x1 Investor Meetings

Conference Dates: September 8-10, 2025

The webcast of the fireside chat will be accessible in the Investor section of the CervoMed website .

About CervoMed

CervoMed is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is currently developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in DLB and certain other major neurological disorders. Neflamapimod is currently being evaluated in a Phase 2b trial in patients with DLB.

Investor Contact:

PJ Kelleher

LifeSci Advisors



617-430-7579



EN
03/09/2025

Underlying

CRVOCERVOMED INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CERVOMED INC

 PRESS RELEASE
Free
CRVO CERVOMED INC

CervoMed Announces New Data from Phase 2b Trial Demonstrating Neflamap...

CervoMed Announces New Data from Phase 2b Trial Demonstrating Neflamapimod's Potential as a Treatment for Dementia with Lewy Bodies Significant improvement relative to placebo on primary outcome measure, change in Clinical Dementia Rating Sum of Boxes (CDR-SB), demonstrated in a within-subject analysis in participants with low likelihood of having Alzheimer’s disease (AD) co-pathology Significant reduction in plasma levels of a well-established biomarker of neurodegeneration, plasma glial fibrillary acidic protein (GFAP), correlated to treatment response assessed by CDR-SB CervoMed antici...

October 8, 2025 1 EN
 PRESS RELEASE
Free
CRVO CERVOMED INC

CervoMed Appoints Matthew Winton, Ph.D., as Chief Commercial and Busin...

CervoMed Appoints Matthew Winton, Ph.D., as Chief Commercial and Business Officer Expanding executive leadership team to prepare for late-stage development, strategic organizational growth, and market readiness BOSTON, Oct. 07, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced the appointment of Matthew Winton, Ph.D., as Chief Commercial and Business Officer. Dr. Winton joins CervoMed with nearly two decades of experience in the global biotechnol...

October 7, 2025 1 EN
 PRESS RELEASE
Free
CRVO CERVOMED INC

CervoMed to Participate in the 4th Annual ROTH Healthcare Opportunitie...

CervoMed to Participate in the 4th Annual ROTH Healthcare Opportunities Conference BOSTON, Oct. 02, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced that Company management will participate in a panel discussion and one-on-one meetings at the upcoming 4th Annual ROTH Healthcare Opportunities Conference being held in New York, NY, on Thursday, October 9, 2025. Panel DetailsTitle: “Small Firms Tackling Blockbuster Indications”Date: Thursday, Octobe...

October 2, 2025 1 EN
 PRESS RELEASE
Free
CRVO CERVOMED INC

CervoMed Highlights Neflamapimod's Potential Benefits in Session on De...

CervoMed Highlights Neflamapimod's Potential Benefits in Session on Dementia with Lewy Bodies at the 150th Annual American Neurology Association Conference BOSTON, Sept. 17, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced that the promising development program and potential benefits of neflamapimod for the treatment of Dementia with Lewy Bodies (DLB) were highlighted in a presentation on advances in DLB drug development by Dr. James Galvin at the...

September 17, 2025 1 EN
 PRESS RELEASE
Free
CRVO CERVOMED INC

CervoMed to Participate in Upcoming Investor Conferences

CervoMed to Participate in Upcoming Investor Conferences BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that Company management will participate in the following investor conferences during the month of September: H.C. Wainwright 27th Annual Global Investment ConferenceFormat: Presentation & 1x1 Investor MeetingsPresentation Date: Monday, September 8, 2025Presentation Time: 2:00 – 2:30 PM ETWebcast: Morgan Stanley’s 23rd Annual Global Healthcare Conf...

September 3, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch